For research use only. Not for therapeutic Use.
Litifilimab is a humanized IgG1-κ antibody targeting to C-type lectin domain family 4 member C (CLEC4C). Litifilimab can be used for cutaneous lupus erythematosus (CLE) study[1][2].
| Catalog Number | I040853 |
| CAS Number | 2407378-48-5 |
| Purity | ≥95% |
| Reference | [1]. Cho SK, et al. Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus. Expert Opin Investig Drugs. 2023 May;32(5):345-353. [2]. Litifilimab. IMGT/mAb-DB. |
